The purpose of this Phase 2 study is to evaluate how the body handles the drug and the drug's effect on the body of participants with mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or mild AD who test positive for amyloid plaque.

Participants are not on a stable standard of care (acetylcholinesterase inhibitors, memantine) initiated less than two months prior to entry or have less than 4 weeks of stable therapy. Note: Stable standard of care is allowed

Have had a serious infectious disease affecting the brain in the past 5 years

Have had a serious or repeat head injury

Have significant retinal impairment or disease

Have had a stroke or other circulation problems that are affecting your current health

Have had a seizure

Have major depressive disorder and are not on a stable dose of medication. Participants who no longer meet the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision (DSM-IV) criteria for major depression may be included

History of schizophrenia, bipolar disorder or severe mental illness.

History of alcohol or drug abuse

Have asthma, chronic obstructive pulmonary disease (COPD) or other breathing disease that is not controlled with medicine

Have human immunodeficiency virus (HIV) or syphilis

Are taking blood thinners

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01561430